ClinicalTrials.Veeva

Menu

Laboratory Studies Into the Pathology of Leukaemia

R

Royal Marsden NHS Foundation Trust

Status

Unknown

Conditions

Leukemia

Treatments

Procedure: Bone Marrow Aspirate

Study type

Observational

Funder types

Other

Identifiers

NCT03233763
CCR4508

Details and patient eligibility

About

Ongoing laboratory work into the pathology of Leukaemia:

Full description

The investigators will test AML samples sent to the diagnostic laboratory from participants with newly diagnosed or relapsed/refractory AML. Samples will be sent from district general hospitals and teaching hospitals.

Results will be returned to referring clinicians in the same way investigators currently return results for samples sent for standard tests. The service will be advertised through the Royal Marsden Website with visibility to both participants and HCPs). The investigators will also inform all the clinicians involved in the AML working party (Dr Taussig is a member of the AML working group).

In addition we are looking at diagnostic approaches to IDH 1 and 2 mutation identification.

An initial comparison of 50 samples by three analysis methods will be conducted.

IDH1 and IDH2 variant discovery will first be performed using an established standard in house SOP (SOP: SMD103) for CE-SSCA

Enrollment

500 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

18 & Over Diagnosis of AML Generic Research consent given

Exclusion criteria

Under 18 No generic research consent

Trial contacts and locations

1

Loading...

Central trial contact

Leonora Conneely

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems